Innoviva, Inc. stock is down -6.18% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 56.25% of the previous 15 February’s closed higher than January.
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!